Nexus OAP slide deck
•
0 likes•188 views
The document discusses a proposed portable ultrasound device project. It aims to create an affordable and easy-to-use portable ultrasound device to fill a gap in the market. The founders are responsible for hardware, software, and regulatory compliance. Market analysis shows strong growth in portable and handheld ultrasound devices. Feedback from customers emphasizes that the device needs to be easy to use, affordable, and better than existing options. The business model may focus on internal medicine, rural, and emergency doctors by prioritizing ease of use, image quality, and portability.
Report
Share
Report
Share
Download to read offline
Recommended
DigiSight Technologies
This document summarizes DigiSight's mission to integrate mobile diagnostic tools into clinical care. It describes that DigiSight currently works with 13 ophthalmic tests on mobile applications and is developing additional tools like fundus imaging and IOP monitoring. The product is a single, secure portal that unites diagnostic data into a complete clinical view for physicians. Use cases show benefits for clinical care, financial performance, and research. Clinical studies have been completed and major partners include retinal specialists. Ophthalmology is a good specialty to start in given concentrated providers and large, motivated patient populations for conditions diagnosed using mobile tools.
Paul Sieving
The National Eye Institute's (NEI) budget for fiscal year 2016 was $695 million, which was used to fund research projects, training, clinical trials, and small business innovation grants. Major initiatives included regenerating neurons and neural connections in the eye through the Audacious Goals Initiative, contributions to the BRAIN Initiative and Precision Medicine Initiative. The NEI supports collaborative research projects, small business grants, and conducts intramural research including stem cell therapy and gene therapy clinical trials. Growing the vision research field through training and diversity programs is also a priority.
Alcon Google Innovation
1) Alcon and Google have partnered to develop "smart lens" technology to address unmet medical needs in eye care, such as treating cataracts, age-related macular degeneration, glaucoma, and presbyopia.
2) The collaboration aims to create glucose-sensing contact lenses to help diabetics manage their condition, and accommodating contact lenses or IOLs to restore near vision for presbyopes.
3) While smart lenses offer advantages like ease of use and data sharing, challenges include ensuring patient privacy as health data is collected and regulatory hurdles in approving new mobile medical devices.
SPOTLIGHT ON THE PREMIUM CHANNEL – Bausch + Lomb
Presentation from OIS@ASCRS 2016
Andrew Chang, General Manager & VP, US Surgical
Video Presentation:
https://www.youtube.com/watch?v=xxXQ5IKIMn8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=36
Nexus oep slide_deck
The document proposes developing an affordable portable ultrasound device to enable widespread screening. It would benefit patients through early detection and be convenient for doctors to use like a stethoscope. The founders aim to market the device to various medical specialties. It outlines the product, team, sales strategy, target customers, costs, revenue projections, potential partners, funding needs, and risks. The goal is for the device to become profitable within 4 years of development and regulatory approval.
High Performance IOL Power Calculation…. at the push of a button
earSight Innovations is developing new technologies that allow accurate measurement of the eye with the ability to move cataract surgery outcomes to a new level. Cataract surgery is the most commonly performed surgery in the world with over 20 million surgeries conducted annually.
Amblyotech
This presentation discusses Amblyotech's binocular treatment for amblyopia. Amblyopia affects 3% of the global population but current treatments like patching are only 25% effective. Amblyotech uses binocular video games calibrated for each patient to simultaneously stimulate both eyes, requiring the brain to accept input from both eyes. Their treatment showed 95% efficacy with just one hour daily for six weeks and no relapses, compared to patching which often fails after six months. The presentation outlines Amblyotech's intellectual property, partnerships with game developers and pediatric eye researchers, and experienced management team developing the first effective and compliant amblyopia treatment.
Second Sight
- Second Sight develops the Argus II retinal prosthesis system which has been approved in the US, EU, Canada and Turkey to restore vision to blind patients.
- They have a large addressable market of over 8 million blind patients globally and are working to expand into additional causes of blindness like AMD.
- They have a strong patent portfolio, experienced leadership, and over $21 million in cash to support their commercialization and research efforts to develop new technologies like a cortical implant.
Recommended
DigiSight Technologies
This document summarizes DigiSight's mission to integrate mobile diagnostic tools into clinical care. It describes that DigiSight currently works with 13 ophthalmic tests on mobile applications and is developing additional tools like fundus imaging and IOP monitoring. The product is a single, secure portal that unites diagnostic data into a complete clinical view for physicians. Use cases show benefits for clinical care, financial performance, and research. Clinical studies have been completed and major partners include retinal specialists. Ophthalmology is a good specialty to start in given concentrated providers and large, motivated patient populations for conditions diagnosed using mobile tools.
Paul Sieving
The National Eye Institute's (NEI) budget for fiscal year 2016 was $695 million, which was used to fund research projects, training, clinical trials, and small business innovation grants. Major initiatives included regenerating neurons and neural connections in the eye through the Audacious Goals Initiative, contributions to the BRAIN Initiative and Precision Medicine Initiative. The NEI supports collaborative research projects, small business grants, and conducts intramural research including stem cell therapy and gene therapy clinical trials. Growing the vision research field through training and diversity programs is also a priority.
Alcon Google Innovation
1) Alcon and Google have partnered to develop "smart lens" technology to address unmet medical needs in eye care, such as treating cataracts, age-related macular degeneration, glaucoma, and presbyopia.
2) The collaboration aims to create glucose-sensing contact lenses to help diabetics manage their condition, and accommodating contact lenses or IOLs to restore near vision for presbyopes.
3) While smart lenses offer advantages like ease of use and data sharing, challenges include ensuring patient privacy as health data is collected and regulatory hurdles in approving new mobile medical devices.
SPOTLIGHT ON THE PREMIUM CHANNEL – Bausch + Lomb
Presentation from OIS@ASCRS 2016
Andrew Chang, General Manager & VP, US Surgical
Video Presentation:
https://www.youtube.com/watch?v=xxXQ5IKIMn8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=36
Nexus oep slide_deck
The document proposes developing an affordable portable ultrasound device to enable widespread screening. It would benefit patients through early detection and be convenient for doctors to use like a stethoscope. The founders aim to market the device to various medical specialties. It outlines the product, team, sales strategy, target customers, costs, revenue projections, potential partners, funding needs, and risks. The goal is for the device to become profitable within 4 years of development and regulatory approval.
High Performance IOL Power Calculation…. at the push of a button
earSight Innovations is developing new technologies that allow accurate measurement of the eye with the ability to move cataract surgery outcomes to a new level. Cataract surgery is the most commonly performed surgery in the world with over 20 million surgeries conducted annually.
Amblyotech
This presentation discusses Amblyotech's binocular treatment for amblyopia. Amblyopia affects 3% of the global population but current treatments like patching are only 25% effective. Amblyotech uses binocular video games calibrated for each patient to simultaneously stimulate both eyes, requiring the brain to accept input from both eyes. Their treatment showed 95% efficacy with just one hour daily for six weeks and no relapses, compared to patching which often fails after six months. The presentation outlines Amblyotech's intellectual property, partnerships with game developers and pediatric eye researchers, and experienced management team developing the first effective and compliant amblyopia treatment.
Second Sight
- Second Sight develops the Argus II retinal prosthesis system which has been approved in the US, EU, Canada and Turkey to restore vision to blind patients.
- They have a large addressable market of over 8 million blind patients globally and are working to expand into additional causes of blindness like AMD.
- They have a strong patent portfolio, experienced leadership, and over $21 million in cash to support their commercialization and research efforts to develop new technologies like a cortical implant.
Gobiquity
Gobiquity creates mobile diagnostic solutions to enable early detection and prevention of vision impairment through broad access. Their flagship product, GoCheck Kids, is a clinically validated mobile photoscreener that identifies Amblyopia Risk Factors. It has experienced rapid adoption, screening over 39,000 children across 25 states. Gobiquity plans to evolve the platform into a comprehensive digital diagnostics suite to address additional large vision markets like age-related macular degeneration and diabetic retinopathy that affect millions. Their uniquely positioned solutions leverage a hybrid team's expertise in mobile imaging, ophthalmology, and commercialization to improve outcomes through scalable and accurate telehealth services.
Revision Optics
This document discusses the Raindrop treatment for presbyopia, which involves placing a small hydrogel inlay under the cornea's surface to improve near and intermediate vision. It provides data on the large market opportunity for presbyopia treatments, details on the Raindrop inlay design and mechanism of action, and clinical trial results demonstrating improvements in near/intermediate vision, visual symptoms, night driving, and patient satisfaction. The regulatory and clinical trial timelines are outlined, as well as the commercial strategy for an international launch following US approval.
RPS Diagnostics
1. RPS Diagnostics develops novel point-of-care technology platforms, reagents, and therapeutic agents for eye care and infectious disease testing.
2. Their proprietary platforms include InflammaDry for dry eye detection and FebriDx for respiratory fever testing. They have 3 additional POC tests in clinical trials and a robust pipeline of products.
3. Their products help physicians provide better patient management by reducing misdiagnosis, unnecessary treatment, and disease spread through rapid, easy-to-use testing. This improves patient outcomes and lowers costs.
Avedro
The document summarizes updates on corneal cross-linking (CXL) technology from Avedro, including:
1) In March 2015, Avedro received a letter from the FDA requesting further information about equivalency between study devices and commercial systems for CXL to treat keratoconus and ectasia.
2) Agreement was reached on additional measurements required to address the FDA's questions. The application was resubmitted in October 2015.
3) Preliminary data is presented on trials of a new CXL technique called PiXL for treating myopia, keratoconus, and post-cataract refractive error, showing safety and efficacy.
Eleven BioTherapeutics
This presentation discusses Eleven Biotherapeutics' development pipeline and upcoming milestones. Eleven is developing two protein therapeutics: Isunakinra, a topical IL-1 receptor blocker in Phase 3 for allergic conjunctivitis, with topline data expected in 1Q16; and EBI-031, a long-acting intravitreal IL-6 antibody planned to enter IND in 1H16 for diabetic macular edema and uveitis. The company highlighted opportunities for these programs to address unmet needs in large ophthalmic markets and provided an overview of upcoming clinical trial timelines and goals.
Forsight Vision5
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
Alcon
The document discusses accelerating innovation in ophthalmology. It notes that innovation requires focusing on patient needs, organizing for success, and making thoughtful choices regarding product innovation, disruptive platforms, delivery models, and other areas. Specific examples are provided of Alcon's innovations in cataract surgery, glaucoma surgery, vitreoretinal surgery, refractive surgery, and retinal pharmaceuticals. Alcon's collaboration with Google on non-invasive sensors and microchips is also mentioned as a potential disruptive platform.
Aura
This corporate presentation outlines Aura Biosciences' novel targeted therapy approach using viral-like particles to treat cancer. Their lead product, AU-011, is being developed for the treatment of ocular melanoma, an orphan disease with no approved therapies. Preclinical data shows AU-011 effectively targets and kills tumor cells through a unique mechanism of action. Aura plans to initiate clinical trials in Q1-2/2016 to obtain proof of concept data and accelerate approval. If approved, AU-011 could be the first FDA-approved treatment for the primary tumor in ocular melanoma patients.
Kikinis, Ron - Basic Software Research in Image Guided Therapy
This document discusses basic software research in image-guided therapy. It describes how research progresses from algorithms and prototypes, to tools for translational research, and eventually to commercially available clinical devices. It emphasizes that open-source software can help reduce duplication of efforts, facilitate collaboration between researchers, and provide a platform for interfacing research applications with clinical devices. The document also provides an overview of the Advanced Multimodality Image Guided Operating suite and some of the clinical research it enables.
Ocular Therapeutix
Ocular Therapeutix "Transforming the Treatment of Eye Diseases with Sustained Release Therapies" Presentation from OIS@ASCRS 2015
Kala Pharmaceuticals
Kala Pharmaceuticals "Penetrating Mucosal Barriers to Maximize Ocular Therapeutic Outcome" presentation from OIS@ASCRS
Allegro
Luminate is a drug being developed by Allegro Ophthalmics to treat retinal diseases. It works through a novel anti-integrin mechanism of action compared to existing anti-VEGF drugs. Phase 2 studies showed Luminate had a 65% efficacy rate in resolving vitreomacular traction, a robust safety profile, and durability of at least 3 months in treating diabetic macular edema and wet age-related macular degeneration. Ongoing phase 2b studies are further evaluating Luminate's potential to treat diabetic macular edema, proliferative vitreoretinopathy, and as an alternative to anti-VEGF drugs with longer duration of effect.
Ocular Imaging Challenge Webinar
This document summarizes a webinar for the ONC Ocular Imaging Challenge. The challenge calls for the creation of an app that improves interoperability between ophthalmic devices, measurement tools, and electronic health records. Specifically, the app should convert data from legacy eye devices to standard formats, archive images and data from multiple sources, display images and data, and integrate with EHRs. The top prize is $100,000. Submissions will be judged on criteria such as the breadth of supported devices, usability, workflow integration, and EHR compatibility. The submission period runs from May 14, 2012 to November 9, 2012.
Kostaras nikos general manager ims
This document discusses clinical trial optimization and the challenges facing the pharmaceutical industry. It notes that the average time to bring a new drug to market is 6-7 years, with 7-9% of R&D budgets spent on clinical trials. Key industry trends include increased focus on safety and efficacy by regulators, scrutiny of cost effectiveness by payers, and industry priorities around cost efficiency and speed. The document outlines challenges such as lack of evidence-based decision making, costly delays, unrealistic trial criteria, and inefficient processes. It presents IMS Health's portfolio of clinical trial optimization solutions to help customers with trial planning, execution, and initiation through the use of technology, data, and analytics. Case studies show benefits such as increased recruitment rates
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
Presbyopia Therapies is developing LiquidVision Eye Drops to treat presbyopia, a large global market affecting most people over age 50. The drops aim to improve near vision without distance vision blur for 5+ hours after a single daily dose. Currently, the main treatment options are reading glasses or contact lenses. A phase 2a trial in 2016 showed the drops improved uncorrected near vision versus placebo. A phase 2b trial beginning in Q2 2017 aims to demonstrate a 30 minute onset and 5+ hour duration with a 3-line improvement in near vision. The company hopes to create a new global market category for the daily treatment of presbyopia.
Jade Therapeutics
This document discusses Jade's proprietary modified hyaluronic acid (CMHA-S) technology for ophthalmic applications. CMHA-S can be used as a standalone therapy for dry eye and corneal repair, or as a drug delivery vehicle for sustained release of small and large molecules to treat ocular diseases. Preclinical studies show CMHA-S eye drops improve dry eye symptoms compared to HA solution. The management team has extensive ophthalmic drug development experience. Near-term goals include clinical studies and regulatory approval of a CMHA-S ocular lubricant in the US and EU, as well as partnering opportunities and a Series A financing round to advance the CMHA-S platform.
Alphaeon
This document discusses ALPHAEON's social commerce ecosystem for disrupting self-pay healthcare. It summarizes that ALPHAEON operates a crowd-sourced network of leading plastic surgeons, ophthalmologists, and dermatologists. Physicians earn "Shout points" through community engagement, which provides rewards like product discounts and patient leads. Elite physicians can earn ALPHAEON franchises. ALPHAEON plans direct-to-consumer marketing in Q4 2015 to introduce its brand and drive more patients and membership. It also plans a consumer app for wellness, beauty, and performance access. ALPHAEON is positioned to lead the large and growing self-pay healthcare market.
Envisia Therapeutics
This document summarizes corporate milestones and pipeline for Envisia Therapeutics, a company developing ophthalmic drug delivery systems. Key points include:
- The company was formed in 2013 and has raised $25 million in funding.
- They are developing long-acting biodegradable formulations of travoprost (ENV515) for glaucoma and difluprednate (ENV905) for post-cataract inflammation. Clinical trials are underway.
- Their PRINT technology platform can produce particles from 100nm to 1000um and is being used to develop extended release formulations of small molecules and biologics for front and back of the eye diseases.
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
This document discusses opportunities and challenges of using mobile health technologies, wearables, and sensors in pharmaceutical research. It describes a vision for the clinical research of the future where patients can be directly dosed, monitored, and engaged through digital tools from their home. Examples are provided of how electronic patient-reported outcomes, biosensors, medical records, drug delivery, and a study companion app could be integrated into a direct-to-patient research model over the course of a day. The document also outlines considerations for determining whether a particular digital health approach or device is well-suited for integration into a patient registry.
4 Strategies to Influence Digital Health Approaches in Clinical Research Studies
Drug Information Association (DIA) 2016 Conference presentation by John Reites on June 26, 2016. Session entitled; "Digital Health Debate" including this presentation on the four strategies to influence digital health approaches in clinical research studies.
Pre Budget Expectations 2013-14
Prepared by our research team check out the 2013 Pre-Budget Expectations
Nexus slide deck
The document discusses a new ultrasound tablet called Nexus that features an on-screen user interface and control compared to traditional cart-based ultrasound devices with knobs. It seeks feedback on focusing on portability, ensuring security on the device and in data transmission, and how to train doctors to use the new portable device.
More Related Content
What's hot
Gobiquity
Gobiquity creates mobile diagnostic solutions to enable early detection and prevention of vision impairment through broad access. Their flagship product, GoCheck Kids, is a clinically validated mobile photoscreener that identifies Amblyopia Risk Factors. It has experienced rapid adoption, screening over 39,000 children across 25 states. Gobiquity plans to evolve the platform into a comprehensive digital diagnostics suite to address additional large vision markets like age-related macular degeneration and diabetic retinopathy that affect millions. Their uniquely positioned solutions leverage a hybrid team's expertise in mobile imaging, ophthalmology, and commercialization to improve outcomes through scalable and accurate telehealth services.
Revision Optics
This document discusses the Raindrop treatment for presbyopia, which involves placing a small hydrogel inlay under the cornea's surface to improve near and intermediate vision. It provides data on the large market opportunity for presbyopia treatments, details on the Raindrop inlay design and mechanism of action, and clinical trial results demonstrating improvements in near/intermediate vision, visual symptoms, night driving, and patient satisfaction. The regulatory and clinical trial timelines are outlined, as well as the commercial strategy for an international launch following US approval.
RPS Diagnostics
1. RPS Diagnostics develops novel point-of-care technology platforms, reagents, and therapeutic agents for eye care and infectious disease testing.
2. Their proprietary platforms include InflammaDry for dry eye detection and FebriDx for respiratory fever testing. They have 3 additional POC tests in clinical trials and a robust pipeline of products.
3. Their products help physicians provide better patient management by reducing misdiagnosis, unnecessary treatment, and disease spread through rapid, easy-to-use testing. This improves patient outcomes and lowers costs.
Avedro
The document summarizes updates on corneal cross-linking (CXL) technology from Avedro, including:
1) In March 2015, Avedro received a letter from the FDA requesting further information about equivalency between study devices and commercial systems for CXL to treat keratoconus and ectasia.
2) Agreement was reached on additional measurements required to address the FDA's questions. The application was resubmitted in October 2015.
3) Preliminary data is presented on trials of a new CXL technique called PiXL for treating myopia, keratoconus, and post-cataract refractive error, showing safety and efficacy.
Eleven BioTherapeutics
This presentation discusses Eleven Biotherapeutics' development pipeline and upcoming milestones. Eleven is developing two protein therapeutics: Isunakinra, a topical IL-1 receptor blocker in Phase 3 for allergic conjunctivitis, with topline data expected in 1Q16; and EBI-031, a long-acting intravitreal IL-6 antibody planned to enter IND in 1H16 for diabetic macular edema and uveitis. The company highlighted opportunities for these programs to address unmet needs in large ophthalmic markets and provided an overview of upcoming clinical trial timelines and goals.
Forsight Vision5
1) ForSight Vision5 is developing the Helios Ocular Insert, a biodegradable insert placed in the eye by a physician that is designed to slowly release bimatoprost over 6 months to lower intraocular pressure and improve patient adherence to glaucoma treatment.
2) Phase 1 and 2 clinical trials showed the insert was well-tolerated and provided sustained IOP-lowering for up to 6 months from a single administration.
3) The company plans to begin a Phase 3 clinical trial program in early 2016 to support regulatory approval and commercialization of the Helios Insert for glaucoma.
Alcon
The document discusses accelerating innovation in ophthalmology. It notes that innovation requires focusing on patient needs, organizing for success, and making thoughtful choices regarding product innovation, disruptive platforms, delivery models, and other areas. Specific examples are provided of Alcon's innovations in cataract surgery, glaucoma surgery, vitreoretinal surgery, refractive surgery, and retinal pharmaceuticals. Alcon's collaboration with Google on non-invasive sensors and microchips is also mentioned as a potential disruptive platform.
Aura
This corporate presentation outlines Aura Biosciences' novel targeted therapy approach using viral-like particles to treat cancer. Their lead product, AU-011, is being developed for the treatment of ocular melanoma, an orphan disease with no approved therapies. Preclinical data shows AU-011 effectively targets and kills tumor cells through a unique mechanism of action. Aura plans to initiate clinical trials in Q1-2/2016 to obtain proof of concept data and accelerate approval. If approved, AU-011 could be the first FDA-approved treatment for the primary tumor in ocular melanoma patients.
Kikinis, Ron - Basic Software Research in Image Guided Therapy
This document discusses basic software research in image-guided therapy. It describes how research progresses from algorithms and prototypes, to tools for translational research, and eventually to commercially available clinical devices. It emphasizes that open-source software can help reduce duplication of efforts, facilitate collaboration between researchers, and provide a platform for interfacing research applications with clinical devices. The document also provides an overview of the Advanced Multimodality Image Guided Operating suite and some of the clinical research it enables.
Ocular Therapeutix
Ocular Therapeutix "Transforming the Treatment of Eye Diseases with Sustained Release Therapies" Presentation from OIS@ASCRS 2015
Kala Pharmaceuticals
Kala Pharmaceuticals "Penetrating Mucosal Barriers to Maximize Ocular Therapeutic Outcome" presentation from OIS@ASCRS
Allegro
Luminate is a drug being developed by Allegro Ophthalmics to treat retinal diseases. It works through a novel anti-integrin mechanism of action compared to existing anti-VEGF drugs. Phase 2 studies showed Luminate had a 65% efficacy rate in resolving vitreomacular traction, a robust safety profile, and durability of at least 3 months in treating diabetic macular edema and wet age-related macular degeneration. Ongoing phase 2b studies are further evaluating Luminate's potential to treat diabetic macular edema, proliferative vitreoretinopathy, and as an alternative to anti-VEGF drugs with longer duration of effect.
Ocular Imaging Challenge Webinar
This document summarizes a webinar for the ONC Ocular Imaging Challenge. The challenge calls for the creation of an app that improves interoperability between ophthalmic devices, measurement tools, and electronic health records. Specifically, the app should convert data from legacy eye devices to standard formats, archive images and data from multiple sources, display images and data, and integrate with EHRs. The top prize is $100,000. Submissions will be judged on criteria such as the breadth of supported devices, usability, workflow integration, and EHR compatibility. The submission period runs from May 14, 2012 to November 9, 2012.
Kostaras nikos general manager ims
This document discusses clinical trial optimization and the challenges facing the pharmaceutical industry. It notes that the average time to bring a new drug to market is 6-7 years, with 7-9% of R&D budgets spent on clinical trials. Key industry trends include increased focus on safety and efficacy by regulators, scrutiny of cost effectiveness by payers, and industry priorities around cost efficiency and speed. The document outlines challenges such as lack of evidence-based decision making, costly delays, unrealistic trial criteria, and inefficient processes. It presents IMS Health's portfolio of clinical trial optimization solutions to help customers with trial planning, execution, and initiation through the use of technology, data, and analytics. Case studies show benefits such as increased recruitment rates
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
Presbyopia Therapies is developing LiquidVision Eye Drops to treat presbyopia, a large global market affecting most people over age 50. The drops aim to improve near vision without distance vision blur for 5+ hours after a single daily dose. Currently, the main treatment options are reading glasses or contact lenses. A phase 2a trial in 2016 showed the drops improved uncorrected near vision versus placebo. A phase 2b trial beginning in Q2 2017 aims to demonstrate a 30 minute onset and 5+ hour duration with a 3-line improvement in near vision. The company hopes to create a new global market category for the daily treatment of presbyopia.
Jade Therapeutics
This document discusses Jade's proprietary modified hyaluronic acid (CMHA-S) technology for ophthalmic applications. CMHA-S can be used as a standalone therapy for dry eye and corneal repair, or as a drug delivery vehicle for sustained release of small and large molecules to treat ocular diseases. Preclinical studies show CMHA-S eye drops improve dry eye symptoms compared to HA solution. The management team has extensive ophthalmic drug development experience. Near-term goals include clinical studies and regulatory approval of a CMHA-S ocular lubricant in the US and EU, as well as partnering opportunities and a Series A financing round to advance the CMHA-S platform.
Alphaeon
This document discusses ALPHAEON's social commerce ecosystem for disrupting self-pay healthcare. It summarizes that ALPHAEON operates a crowd-sourced network of leading plastic surgeons, ophthalmologists, and dermatologists. Physicians earn "Shout points" through community engagement, which provides rewards like product discounts and patient leads. Elite physicians can earn ALPHAEON franchises. ALPHAEON plans direct-to-consumer marketing in Q4 2015 to introduce its brand and drive more patients and membership. It also plans a consumer app for wellness, beauty, and performance access. ALPHAEON is positioned to lead the large and growing self-pay healthcare market.
Envisia Therapeutics
This document summarizes corporate milestones and pipeline for Envisia Therapeutics, a company developing ophthalmic drug delivery systems. Key points include:
- The company was formed in 2013 and has raised $25 million in funding.
- They are developing long-acting biodegradable formulations of travoprost (ENV515) for glaucoma and difluprednate (ENV905) for post-cataract inflammation. Clinical trials are underway.
- Their PRINT technology platform can produce particles from 100nm to 1000um and is being used to develop extended release formulations of small molecules and biologics for front and back of the eye diseases.
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
This document discusses opportunities and challenges of using mobile health technologies, wearables, and sensors in pharmaceutical research. It describes a vision for the clinical research of the future where patients can be directly dosed, monitored, and engaged through digital tools from their home. Examples are provided of how electronic patient-reported outcomes, biosensors, medical records, drug delivery, and a study companion app could be integrated into a direct-to-patient research model over the course of a day. The document also outlines considerations for determining whether a particular digital health approach or device is well-suited for integration into a patient registry.
4 Strategies to Influence Digital Health Approaches in Clinical Research Studies
Drug Information Association (DIA) 2016 Conference presentation by John Reites on June 26, 2016. Session entitled; "Digital Health Debate" including this presentation on the four strategies to influence digital health approaches in clinical research studies.
What's hot (20)
Kikinis, Ron - Basic Software Research in Image Guided Therapy
Kikinis, Ron - Basic Software Research in Image Guided Therapy
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
Opportunities and Challenges of Mobile Health, Wearables and Sensors for Pharma
4 Strategies to Influence Digital Health Approaches in Clinical Research Studies
4 Strategies to Influence Digital Health Approaches in Clinical Research Studies
Viewers also liked
Pre Budget Expectations 2013-14
Prepared by our research team check out the 2013 Pre-Budget Expectations
Nexus slide deck
The document discusses a new ultrasound tablet called Nexus that features an on-screen user interface and control compared to traditional cart-based ultrasound devices with knobs. It seeks feedback on focusing on portability, ensuring security on the device and in data transmission, and how to train doctors to use the new portable device.
森林セラピーと企業研修と妙高高原のリソースの融合で 中堅世代の心とからだをサポートする事業
中堅世代のビジネスパーソンが抱えるストレスを、地域が持つ自然のリソースを活かして改善すると共に、ストレスの根本原因である職場環境や人間関係を、コミュニケーション力を使って改善できるよう、企業研修や講座を開催するプログラムを開発するプロジェクト。
Sketches
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
Select ex standfordproductinformation
This document discusses a meCommerce cloud platform called Mass Customization 2.0 that allows for custom product configuration. It includes high-level components like a template engine, visual product configurator, SelectManager desktop app, SelectStore web store, and SelectBuilder template creation tool. The template engine is at the core, supporting complex and customizable product structures. SelectManager is for sales, customer service, and management. SelectStore is the customer-facing web store. SelectBuilder helps product engineers easily create advanced configurable templates. The goal is to provide an enterprise e-commerce platform that supports complex product customization through visualization.
Acmiil Research - What We Do?
We are one of the few brokerage houses to have a research team dedicated to serve the needs of retail investors. The retail research team of ACMIIL is strongly committed to perform professional and insightful research and believes in sharing its profitable discoveries with its investors
Smartanglers PPT
Smartanglers.net is an HR services company located in Bangalore, India that has been in operation since 2003. It has expertise in executive search, recruitment, HR consulting, and acting as a process partner for clients' HR functions and processes. The company aims to provide customized solutions to clients' HR needs, ensure customer satisfaction, and help organizations focus on their core business by outsourcing HR activities. It has worked with over 30 companies across various industries. The leadership team includes Rohini Hande and Gurudath Hegde, who have decades of combined experience in HR.
What is Capital Market?
"This presentation covers the fundamentals of the Indian capital markets. It includes a briefing on the various instruments available for fund raising and investing. It will help you understand the basics of shares, debentures, bonds, commodities and other instruments".
Non Convertible Debentures
Debenture is a debt instrument which is used by companies to borrow money from general public. Here's a presentation that tells you everything you need to know about Non Convertible Debentures
Equity Investment
This document provides guidance for first time equity investors. It outlines several important points for new investors to consider:
1) Know the rules of the equity market and understand your purpose for investing - whether it is for savings or surplus funds - to help choose appropriate stocks.
2) Keep a clear time objective in mind for both buying and selling stocks to help achieve your investment goals.
3) Understand your risk profile as an aggressive, moderate, or defensive investor to select stocks that match your risk tolerance.
4) Invest in industries you have expertise in to better understand growth prospects and risks.
5) Stay updated on your stock investments through research and avoid relying on tips or rumors.
Viewers also liked (13)
Similar to Nexus OAP slide deck
Next generation family diagnostic analysers
IDR Medical's Case Study. The client company is a global leader in its field of laboratory diagnostics, their range of devices is immensely successful, but there is a need to evolve and stay at the forefront of the market.
IDR Medical is an international marketing consultancy company with local offices in the UK, the US and Switzerland.
What are leadership The simple definizion is that leadership - is
What are leadership? The simple definizion is that leadership - is the art of motivating a group of people to act toward achieving a common goal. In a business setting it can mean directing workers and colleagues with a strategy to meet the company's needs.
This leadership definition captures the essentials of being able and prepared to inspire others. Effective leadership is based upon ideas (whether original or borrowed), but won't happen unless those ideas can be communicated to others in a way that engages them enough to act as the leader wants them to act.
Put even more simply, the leader is the inspiration for and director of the action. They are a person in the group that possesses the combination of personality and leadership skills to make others want to follow their direction.
<To develop a new medical device for China market >
< PMGT 699 – Applied Project Management >
Prepared By
< Soumitra G Shilotri >
<02/11/2020>
1.Executive Summary 3
2.Project Overview 5
2.1 Project Description 5
2.2 Problem Statement 5
2.3 Goals 5
2.4 Project Background 7
2.5 Product Objectives 7
2.6 Assumptions, Constraints and Dependencies 7
2.7 Project Deliverables 8
2.8 Schedule and Budget Summary 9
2.9 Evolution of the Plan 10
2.10 Definitions and Acronyms 10
3.Stakeholder Register 12
4.Schedule Component 14
5.Resource Plan with RACI 18
5.1Overview/Purpose 18
5.2 Resourcing Strategy & Assumption 18
5.3 Resourcing Development 18
6.Risk Management Plan 21
6.1 Review of Risk Management Plan 21
6.2 Risk Identification 21
7.Communications Plan 24
8. Procurement 28
9. Cost…………………………………………………………………………………………..30
10. Integrated Change Control 341.Executive Summary
1.1 Introduction
Johnson and Johnson (J&J) is an American multinational company that develops medical devices, pharmaceutical drugs and consumer products. J&J is one of the largest medical device companies in the world. There are various subsidiaries of J&J, however the medical device business of J&J includes 3 global franchises; mainly Ethicon (surgical), Bio-sense Webster (Cardiovascular & Speciality solutions) and Depuy Synthes (Orthopaedics). J&J has a presence in over 100 countries worldwide and the medical device companies manufactures and does R&D on various different kinds of surgical devices, implants that are used by doctors in laparoscopic surgeries.
Current project that I will be working on is named as Project RoadRunner by the project team. The project is to develop a new medical device implant for China market. The implant is a sterile product that is used by surgeons during bariatric surgeries. This implant is used alongside a vascular stapler and will improve the staple line integrity, force to fire and staple performance during surgery. This will be a big boost in the existing line of stapling implants by improving performance reliability and decrease market complaints. So far for earlier legacy devices, we were using 2-D st ...
Innovega e macula eyewear 2019
Innovega is developing a transformative eyewear system called eMacula that combines smart contact lenses and stylish glasses. The system will provide unprecedented assistance to the 15 million visually impaired through magnification and enhancement of the wearer's vision. It will also open new mass consumer markets by offering normal, stylish glasses that provide augmented and virtual reality experiences. Innovega has assembled a team with experience from Microsoft, Sony, and Bausch + Lomb and has investors including Tencent. Clinical trials are underway and FDA approval is being pursued to bring the innovative product to market.
Oxford AHSN Map My App Event 29th Jan 2014
The document outlines a 6 stage process for developing mobile health apps for the NHS. It discusses evaluating needs and requirements, designing prototypes, user testing, stakeholder reviews, medical device approvals if needed, and finally external deployment including options for commercialization. It provides background on the growing market for mHealth apps and considerations around ensuring patient safety, data privacy, and addressing a fragmented Android environment.
Implementing a New Clinical Systems Strategy
Intersect ENT, a medical device organization, takes a company-wide approach to successfully managing clinical trial data and systems.
iMPak Health Kraken Allscripts open app challenge
The document discusses the Kraken Medication Management Solution created by Allscripts Healthcare Solutions to address the problems of low prescription medication compliance rates in the US. The solution involves a low-cost device and mobile application that tracks patient medication compliance and shares the data with physicians and patients. It aims to improve management of chronic diseases and support value-based care by maximizing the benefits of prescribed medications through enhanced monitoring and compliance. The solution is currently in development and plans are outlined for integrating it with Allscripts solutions, establishing pricing, distribution channels, and selecting the solution.
Time and cost savings of using continua pw c
The document discusses the benefits of implementing the design guidelines from Continua Health Alliance, an international non-profit organization that enables connectivity of personal health devices. A survey was conducted of Continua members to quantify the time and cost savings. Case studies found that following Continua guidelines reduced integration time for a device manufacturer from 9 weeks to 3 weeks, saving $130,000, and for a system integrator reduced time from 12 weeks to 2 weeks for a project, saving $140,000. Overall, using Continua guidelines was found to save significant time and costs across organizations.
Robot
Medical technology is focused on providing cheaper, more efficient patient care. The article discusses 5 emerging medical technologies: 1) A skin scanner to reduce unnecessary melanoma biopsies, 2) An implant to treat headaches with nerve stimulation, 3) A non-invasive diabetes sensor, 4) Hospital robots to monitor patients autonomously, and 5) A heart valve replacement procedure using a catheter. While technology can make healthcare cheaper and more accurate, it also risks eliminating jobs and potential reliability issues.
Business model for single port robotic surgery
Single port robotic surgery is gaining popularity due to its benefits over traditional multi-port surgery. A business model and value proposition canvas were created to outline the market opportunity for single port robotic surgery devices. Key opinion leaders and clinical associations were identified as important sources of information to educate medical professionals and accelerate adoption of new technologies. The canvases were modified based on feedback to address user adoption barriers, costs, data management, and focus on continuous research collaboration between doctors and engineers to further develop safe, minimally invasive surgical robotics.
October Webinar: Healthcare Leaves the Desktop
This document summarizes a presentation about how mobile research impacts the healthcare industry. It finds that mobile device usage is growing rapidly among both patients and physicians. Over 80% of doctors use smartphones and 62% use tablets in their practice. The presentation also describes case studies where mobile surveys were effectively used to conduct market research with diabetes patients and physicians. A study of physicians found that most own smartphones and are very interested in participating in mobile surveys on topics like new treatments. The presentation concludes that mobile device usage for patient interactions will continue increasing in the coming years.
COGKNOW: Assistive Technology for People with Mild Dementia - A User-Centred ...
The document summarizes the COGKNOW project, which developed and evaluated an assistive technology called the COGKNOW Day Navigator to help people with mild dementia. The project used a user-centered approach, involving people with dementia and their caregivers to identify needs and evaluate prototypes. Over three iterations, the technology was refined based on user feedback. Evaluation found the reminding and communication functions useful but the safety features needed more development. Overall, users saw benefits for autonomy and quality of life, but longer-term studies are still needed. The project also examined technical, user, and business perspectives to understand factors for real-world implementation.
Parallel Session 1.9 Using Health Analytics for Improved Outcomes
This document summarizes how predictive analytics can be used in healthcare to improve outcomes. It discusses how market forces are requiring a new approach in healthcare due to shifting contexts, changing demographics, and rising costs of chronic diseases. It proposes moving from a doctor-patient model to one that incorporates payers, providers, community, friends, and government. It argues that healthcare organizations should use data-driven insights to determine personalized treatment plans, understand patient attitudes, quantify costs and benefits, and predict treatment effectiveness. The document outlines IBM's healthcare analytics solutions for improving strategic decision making, policies, and enabling operational staff to take next best actions based on predictive models. Case studies are presented on how hospitals in Belgium and Spain used predictive analytics to enable
Cloud Platform for Remote Patient Monitoring. Case: Stroke Remote Care.
Presentation at AI morning in April 13th at Tampere University of Technology Kampusklubi.
"AI Morning in April 13th experiments with a new distinctive concept and remixes together machine learning and analytics in the two verticals of healthcare and industry! There is a huge common ground in diagnostics of people and machines, and the same algorithms can be used in both. The presenters from healthcare and industry keynote a conversational networking forum in theme: 'Health: analytics'."
See http://www.aiaamu.fi/
Connected Health: The Importance of Systems Integration
The document discusses connected health and the importance of systems integration. It notes that barriers to integration include technical standards, regulations, and demonstrating financial value. Drivers for healthcare integration are addressing staffing shortages, developing smart devices, improving processes and reducing costs. A successful solution must consider the complete system from a user, business and technology perspective. The case study describes how Starkey developed a wireless solution called SurfLink Mobile to allow hearing aid users to stream audio from smartphones without a separate relay device.
Designing a Mobile Device Lab - XBOSoft Webinar
Mobile expert Costa Avradopoulos discusses how to build a better mobile device lab in this XBOSoft Webinar.
APT_Indigo FactSheet FINAL
The document describes Aptuit INDiGO's accelerated drug development program. It offers integrated services to help clients advance molecules from candidate selection to clinical trials in as few as 52 weeks. This is significantly faster than the industry average of 122 weeks. Aptuit's program provides world-class expertise across preclinical and clinical development, API manufacturing, and regulatory submission preparation to streamline the process. It aims to reduce costs and development time while improving data quality for clients.
Medical Imaging Seminar Company Presentations
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Ophthalmic Drugs 2017
SMi Group are thrilled to announce the launch of the Ophthalmic Drugs Conference, being held on the 28-29 November 2017 at the Copthorne Tara Hotel in London, UK. www.ophthalmicdrugs.com/slideshare
Lowlesh N Yadav-Paper ID 208 - Copy.pptx
This document discusses the feasibility and challenges of deploying a remote patient monitoring and tele-healthcare system. It proposes developing a system using sensors connected to cloud servers to remotely collect patient health data in real-time. The document outlines plans to test the system by deploying it across multiple hospitals, clinics, urban and rural locations with volunteer patients and health workers. Data collected would then be analyzed to understand effectiveness across patient groups, locations, and diseases to improve the system for remote patient care. The conclusion is that with further testing and support, such a system has potential to improve healthcare access.
Additive Manufacturing in the Medical Field -EOS
The document discusses the benefits of additive manufacturing (AM) for medical applications. AM allows for the production of customized medical implants and instruments tailored specifically for individual patients using 3D CAD data. This enables implants to fit patients perfectly for improved healing and integration with the body. AM also allows for complex geometries and integration of multiple functions into single components not possible with traditional manufacturing. The customized nature and quick production time of AM provides benefits to patients through improved care, surgeons through more precise tools, and hospitals by reducing costs and shortening patient stays.
Similar to Nexus OAP slide deck (20)
What are leadership The simple definizion is that leadership - is
What are leadership The simple definizion is that leadership - is
COGKNOW: Assistive Technology for People with Mild Dementia - A User-Centred ...
COGKNOW: Assistive Technology for People with Mild Dementia - A User-Centred ...
Parallel Session 1.9 Using Health Analytics for Improved Outcomes
Parallel Session 1.9 Using Health Analytics for Improved Outcomes
Cloud Platform for Remote Patient Monitoring. Case: Stroke Remote Care.
Cloud Platform for Remote Patient Monitoring. Case: Stroke Remote Care.
Connected Health: The Importance of Systems Integration
Connected Health: The Importance of Systems Integration
Recently uploaded
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
What are the different types of Dental implants.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
Ageing, the Elderly, Gerontology and Public Health
Challenges associated with ageing from a public health perspective
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort. Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...ayushrajshrivastava7
Regulatory Affairs
Full hand written notes
M.pharm - 1st year .What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
Cervical Disc Arthroplasty ORSI 2024.pptx
Indication and installation of a mobile cervical disc prosthesis. Benefits of the PRODISC C VIVO mobile disc prosthesis (Centinel Spine)
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montrealHow to choose the best dermatologists in Indore.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Nano-gold for Cancer Therapy chemistry investigatory project
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Breast cancer: Post menopausal endocrine therapy
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Recently uploaded (20)
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Nexus OAP slide deck
- 1. Opportunity Analysis Project 11/20/2012
- 2. Main Idea • To build a portable ultrasound device that is easy to use, affordable and still has good image quality for correct diagnosis. • The device would fill the gap that are not targeted by present existing models. 11/20/2012 © Nexus Inc., Company Confidential 2
- 3. Team • Pi Sheng Chang • Co-founder – Responsible for hardware and software/firmware development, product design, device prototyping and system integration. • Peter Chang • Co-founder – Responsible for product marketing, operations, manufacturing oversight, FDA regulatory compliance certification and quality assurance. 11/20/2012 © Nexus Inc., Company Confidential 3
- 4. Market Analysis • Total Global Ultrasound Market: $5B (2009) • U.S. market size: 22%, Europe: 32% • Compound annual growth rate (CAGR, 2009): • Worldwide: 6.5%, China: 9.3%, U.S.: 1%, Europe: 1% • Hand carried CAGR: 32% • Portable CAGR: 17% 11/20/2012 © Nexus Inc., Company Confidential 4
- 5. Target Customers • Worldwide unit shipment (2010): • Cardiologists: 30810 units • OBGYN: 38090 units • Internal Medicine: 6893 units • Radiologists: 47465 units • Emergency Medicine: 4996 units 11/20/2012 © Nexus Inc., Company Confidential 5
- 6. Customers Feedback • It needs to be easy to use: doctors are not usually trained as sonographers to use the full potential of a ultrasound device. If the device is easier to use and meet the doctors’ diagnostic expectations, doctors would use it more often. • It needs to be affordable: Cost is very sensitive to doctors. We need to show how long is the return of investment (ROI) and how doctors can charge for an exam using the device. • The product needs better differentiation compared to existing products: There are other portable ultrasound devices in the market. It is not very clear how the proposed product differentiate from those. • How can it help the doctors to make better diagnosis: Currently, ultrasound imaging is only requested when there is a suspicion of a problem. Early detection is missed if there is no suspicion. An ultrasound scan from the test order to getting the results could take weeks. Having the device in the doctors’ office could shorten the time of getting the results to hours. It is akin to instant gratification. 11/20/2012 © Nexus Inc., Company Confidential 6
- 7. Business Model Changes • Targeted customer segment should be limited to those for whom the portable device is more useful: Internal medicine doctors, doctors in rural areas, emergency medicine doctors, military doctors, etc. • The portable device should be easy to use in the office and in the field. Product differentiation should be focused on ease of use, image quality and portability. 11/20/2012 © Nexus Inc., Company Confidential 7
- 8. Nexus Product Breakthrough advances in user interface and workflow Breakthrough advances in user interface and workflow 11/20/2012 © Nexus Inc., Company Confidential 8